The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)

Consolidated Financial Statements for the Second Quarter Ended September 30, 2020
FY2021 (April 1, 2020 - September 30, 2020) [UNAUDITED]
November 10, 2020
Takara Bio Inc.
Tokyo Stock Exchange (1st section)4974
https://www.takara-bio.co.jp
Koichi Nakao, President
Takuya Kakemi, General Manager of Corporate
Management Division, Executive Officer
Tel. (077) 565-6970
November 12, 2020

Company name:
Stock exchange listings:
Code number:
URL:
Company representative:
Contact:

Scheduled date of quarterly statement filing:
Scheduled date of starting delivery of dividends:－
Supplementary documents of the financial results:
Yes
Financial results information meeting:Yes
Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles andpractices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.
1. Results for the six months ended September 30, 2020 (Apr. 1, 2020 – Sep. 30, 2020)(1) Consolidated operating results(Percentages indicate changes from the same period of the previous fiscal year.)Six months ended
Sep. 30, 2020
Net sales
Operating profit
Ordinary profit
Net income (loss) attributable to owners ofparent
Net income per share (in yen)
Fully diluted net income per share (in yen)
(Note) Comprehensive income(Millions of yen)
17,393
3,736
3,820
2,274
18.89
－
1,608

Six months ended
Sep. 30, 2019
5.7
23.1
29.0
9.6

(Millions of yen)
16,450
3,035
2,961
2,075

(5.3)
15.7
10.9
20.6

(36.0)

17.23
－
1,182

(39.2)(%)(%)(2) Consolidated financial position

Total assets
Net assets
Equity ratio (%)
Net assets per share (in yen)
(Reference) Equity

As of Sep. 30, 2020
(Millions of yen)

As of Mar. 31, 2019
(Millions of yen)

77,343
67,23686.8
557.5067,13175,00966,591
88.7
552.2366,496

2. Dividends
Year ended
Mar. 31, 2020

Year ending
Mar. 31, 2021

Annual dividends per share in yen
Year ending
Mar. 31, 2021 (Forecast)First quarter end－－
Second quarter end
0.00
0.00
Third quarter end－
Year end
8.00
Annual8.00(Note) Revision of dividend payment forecast since the most recently announced payment forecast: Yes

－

9.00
9.00

The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)
3. Forecast for the year ending March 31, 2021 (Apr. 1, 2020 – Mar. 31, 2021)(Percentages indicated changes from the same period of the previous fiscal year.)Year ending Mar. 31, 2021
(Millions of yen)
(Millions of yen)
Net sales
40,800Operating profit
8,000
Ordinary profit
8,100
Net income attributable to owners of the parent
5,000
Net income per share (in yen)
41.52
(Note) Revision of financial forecast since the most recently announced payment forecast: Yes
※

18.0
27.5
27.6
30.9

Others(1) Changes in subsidiaries during the six months ended September 30, 2020
(Changes in specified subsidiaries resulting in change of scope) ： No
Newly included: － (Name)
Excluded: － (Name)(2) Application of special accounting methods to the consolidated quarterly financial statements： No(3) Changes in accounting policies, changes in accounting estimates, and retrospective restatement
1) Changes based on revisions of accounting standard： No
2) Changes other than ones based on revisions of accounting standard： No
3) Changes in accounting estimates： No4) Restatement： No(4) Number of outstanding shares (Common stock)1) Number of outstanding shares at year end (Treasury stocks are included)
120,415,600
As of September 30, 2020
As of March 31, 2020
120,415,600
2) Number of treasury stocks at year end－
As of September 30, 2020－
As of March 31, 2020
3) Average number of outstanding shares
120,415,600
As of September 30, 2020
120,415,600
As of September 30, 2019

※ These financial statements are not subject to auditing.
※ Comment regarding appropriate use of earnings forecasts and other special notes
Forward-looking statements contained in this document are determined by the Takara Bio Company based on information
currently available to the Company and include a number of uncertainties. Actual results could differ from these forecasts due
to changes in conditions that occur in the future. For information regarding the above, please refer to 1. Qualitative Information
for the six months ended September 30, 2020 (4) Qualitative Information Regarding Consolidated Forecasts, on page 2 of theattached document.

The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)

Contents of the attached document
1. Qualitative Information for the six months ended September 30, 2020…………………...........……………………………
(1) Overview of Financial Results……………………………………………………….………….………….…………......
(2) Overview of Financial Position………………………………………………...…………………………...……..............
(3) Overview of Cash Flows…………………………………………………………….…………………………….……....
(4) Qualitative Information Regarding Consolidated Forecasts………………………………………………………………
2. Consolidated Quarterly Financial Statements and Primary Notes…………………………………………………………….
(1) Consolidated Quarterly Balance Sheets…………………………………………………………………………………...
(2) Consolidated Quarterly Statements of Profit or Loss and Consolidated Quarterly Statements of Comprehensive Income……..
(Consolidated Quarterly Statements of Profit or Loss)(For the six months ended September 30, 2020) ……………………………………………………………………
(Consolidated Quarterly Statements of Comprehensive Income)(For the six months ended September 30, 2020) ……………………………………………………………………
(3) Consolidated Quarterly Statements of Cash Flows………………………………………………………………………..
(4) Notes to Consolidated Quarterly Financial Statements……………………………………………………………………
(Notes on Premise of Going Concern) …………………………………………………………………………………..
(Notes in case of Changes in Marked Amount of Shareholders’ Equity) ………………………………………………
(Additional Information)………………………………………………..…………..…………..…………..…………...
(Segment Information)……………………………………………………………………………..……………….……
3. Supplementary Information …………………………………………………………………………………………………..
(1) Trends in Key Management Indicators……………………………………………………………………………………
(2) Comparative Consolidated Statement of Profit or Loss …………………………………………………………………
(3) Comparative Statement of Profit Relating to Consolidated Earnings Forecast…………………………………………

- 1 -

2
2
2
2
2
3
3
5
5
6
7
8
8
8
8
8
9
9
10
11

The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)
1. Qualitative Information for the six months ended September 30, 2020
(1) Overview of Financial Results
In the fiscal year under review, ended September 30, 2020, the global economy has continued to be uncertain due to the influenceof the new Coronavirus disease (COVID-19) pandemic, the trade friction issue in the US and China, and Brexit, etc.
Against these circumstances, under our corporate philosophy of “Contributing to the health of humankind through thedevelopment of revolutionary biotechnologies such as gene therapy”, Takara Bio (the Company) is promoting the development of
bio-drug discovery platform technologies through the businesses of research reagents and scientific instruments and CDMO
business, aiming to become a drug discovery company and continuously creates new modalities in line with “Long-Term
Management Plan FY2026” and “Medium-Term Management Plan FY2023”
As a result, overall net sales in the fiscal year under review, ended September 30, 2020 increased 5.7% year on year to ¥17,393
million, due to the contributions from sales for research reagents and contract services exceeding those of the same period of theprevious fiscal year, despite the decrease in the Gene Therapy compared with the same period of the previous fiscal year. Cost of
sales decreased 9.1% year on year to ¥5,565 million due to the change of sales composition by item and others, and an increase inproduction utilization rates, and gross profit increased 14.5% year on year to ¥11,827 million. Selling, general and administrative(SG&A) expenses increased 10.9% year on year to ¥8,090 million due to the increase in R&D expenses, and the Company recorded
operating profit up 23.1% year on year to ¥3,736 million.
Accompanied with the increase in operating profit, ordinary profit increased 29.0% to ¥3,820 million, profit before income taxes
and others increased 11.2% year on year to ¥3,281 million, and net income attributable to owners of parent increased 9.6% year on
year to ¥2,274 million.
Segment information has been omitted since the reportable segments were changed to a single segment since the three months
ended June 30, 2020. For details, please refer to “2. Consolidated Quarterly Financial Statements and Primary Notes (Segment
Information)”.
(2) Overview of Financial Position
In the fiscal year under review, total assets were ¥77,343 million, an increase of ¥2,334 million compared with that at the end of
the previous fiscal year. This primarily resulted from an increase in non-current assets of ¥3,849 million based on the acquisitionof land and building for the new facility of Takara Bio USA, Inc..
In the fiscal year under review, total liabilities were ¥10,106 million, an increase of ¥1,688 million compared with that at the endof the previous fiscal year. This primarily resulted from an increase of ¥1,021 million in others for current liabilities.
In the fiscal year under review, total net assets stood at ¥67,236 million, an increase of ¥645 million compared with that at theend of the previous fiscal year. The main factor was an increase of ¥1,311 million in retained earnings and a decrease of ¥692
million in foreign currency translation adjustment due to the appreciation of the yen.
(3) Overview of Cash FlowsNet cash provided by operating activities was ¥5,553 million, up by ¥844 million compared with the same period of the previous
fiscal year. This was mainly due to profit before income taxes and others of ¥3,281 million, depreciation and amortization of ¥1,631
million, cash inflow of ¥1,178 million from an increase in current liabilities, and cash outflow of ¥1,481 million from an increase
in inventories.
Net cash provided by investing activities was ¥2,417 million, an increase of ¥133 million compared with the same period of theprevious fiscal year. This was primarily due to ¥5,750 million in payments for purchase of property, plant and equipment andintangible assets, and ¥2,000 million in proceeds from sales and redemption of securities.
Net cash used in financing activities was ¥1,030 million, an increase ¥145 million compared with the same period of the previous
fiscal year. This was primarily because of an increase of ¥961 million in cash dividends paid.
As a result of the above, balance of cash and cash equivalents at the end of second quarter of the current fiscal year, including
the effect of exchange rate change on cash and cash equivalents, stood at ¥16,360 million, up by ¥1,897 million from the previous
fiscal year-end.
(4) Qualitative Information Regarding Consolidated Forecasts
The Company has revised the financial forecast disclosed on August 4, 2020, and the dividend forecast. For details, refer to “NoticeRegarding Forecast Revisions of Financial results and Dividend (Dividend Increase)” disclosed on November 10, 2020.
For comparison between revised forecast for consolidated results, previous period results, and previous forecast, refer to“Comparative Statement of Profit Relating to Consolidated Earnings Forecasts” on page 11.

- 2 -The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)
2. Consolidated Quarterly Financial Statements and Primary Notes(1) Consolidated Quarterly Balance Sheets(Millions of yen)
As of Mar. 31, 2020
AssetsCurrent assets
Cash and deposits
Notes and accounts receivable-tradeMarketable securities
Merchandise and finished goods
Work in process
Raw materials and supplies
Other
Allowance for doubtful accounts
Total current assets
Non-current assets
Property, plant and equipment
Buildings and structures
Accumulated depreciation
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation
Machinery, equipment and vehicles, net
Tools, furniture and fixtures
Accumulated depreciation
Tools, furniture and fixtures, net
LandConstruction in progress
Others
Accumulated depreciation
Others, net
Total Property, plant and equipment
Intangible assets
Goodwill
Other
Total intangible assets
Investments and other assets
Investments and other assets
Total investments and other assets
Total non-current assets
Total assets- 3 -As of Sep. 30, 2020

18,266
9,102
2,000
4,511
1,208
1,874
1,479
(56)
38,387

18,627
8,448
－
4,829
1,410
2,606
1,005
(56)
36,871

16,478(5,630)10,847
6,705(3,353)
3,352
7,912(5,217)
2,694
5,724
85
1,635
(126)
1,509
24,213

15,349(4,746)
10,602
6,895(3,505)
3,389
7,783(5,126)
2,657
8,240
2,518
1,619
(192)
1,426
28,835

7,006
4,348
11,355

6,645
3,627
10,273

1,053
1,053
36,62275,0091,363
1,363
40,472
77,343

The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)(Millions of yen)
As of Sep. 30, 2020

As of Mar. 31, 2020
Liabilities
Current liabilities
Notes and accounts payable-trade
Accrued income taxes
Provision
Other
Total current liabilities
Non-current liabilities
Retirement benefit liabilities
Other
Total non-current liabilities
Total liabilities
Net assets
Shareholders’ equity
Share capital
Capital surplus
Retained earnings
Total shareholders' equity
Accumulated other comprehensive income
Foreign currency translation adjustment
Remeasurements of retirement benefit
Total accumulated other comprehensive income
Non-controlling interests
Total net assets
Total liabilities and net assets

- 4 -

1,027
683
557
3,978
6,248

1,366
1,024
605
5,000
7,996

783
1,386
2,169
8,418

775
1,334
2,110
10,106

14,96532,89318,501
66,36014,96532,893
19,812
67,672

436
(300)
135
95
66,59175,009

(256)
(283)
(540)
104
67,236
77,343

The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)(2) Consolidated Quarterly Statements of Profit or Loss and Consolidated Quarterly Statements of Comprehensive Income(Consolidated Quarterly Statements of Profit or Loss)(For the six months ended September 30, 2020)(Millions of yen)Six months ended
Sep. 30, 2020

Six months ended
Sep. 30, 2019
Net sales
Cost of sales
Gross profit
SG&A expenses
Employees' salaries and bonuses
Retirement benefit expenses
R&D expenses
Provision for doubtful accounts and bonuses
Other
Total SG&A expenses
Operating profit
Non-operating profit
Interest income
Foreign exchange gains
Rent income from real estate
Other
Total non-operating profit
Non-operating expenses
Interest expenses
Foreign exchange loss
Rent expenses on real estate
Expenses of inactive non-current assets
Other
Total non-operating expenses
Ordinary profit
Extraordinary profit
Gain on sale of fixed assets
Total extraordinary profit
Extraordinary losses
Loss on sale and retirement of fixed assets
Loss on business liquidation
Loss on sale of investment securities
Other
Total extraordinary losses
Profit before income taxes and others
Income taxes-current
Income taxes-deferred
Total income taxes
Net income
Net income attributable to non-controlling interest
Net income attributable to owners of the parent- 5 -16,450
6,121
10,32917,393
5,565
11,827

1,957
89
1,858
267
3,121
7,293
3,035

2,082
98
2,403
291
3,214
8,090
3,736

59
－
53
17
130

60
2
61
18
143

－
176
17
1
8
203
2,961

12
－
24
19
3
59
3,820

0
0

1
1

9
－
2
－
12
2,950
665
205
870
2,080
4
2,075

25
464
－
49
539
3,281
1,203
(212)
990
2,291
16
2,274

The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)(Consolidated Quarterly Statements of Comprehensive Income)(For the six months ended September 30, 2020)(Millions of yen)Six months ended
Sep. 30, 2020

Six months ended
Sep. 30, 2019
Net income
Other comprehensive income
Foreign currency translation adjustment
Remeasurements of retirement benefit
Total other comprehensive income
Comprehensive income
Comprehensive income attributable to:
Owners of the parent
Non-controlling interest

- 6 -

2,080

2,291

(909)
12
(897)
1,182

(699)
16
(683)
1,608

1,179
3

1,598
9

The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)(3) Consolidated Quarterly Statements of Cash Flows(Millions of yen)Six months ended
Sep. 30, 2019
Net cash provided by (used in) operating activities
Profit before income taxes and others
Depreciation and amortization
Depreciation and amortization on other
Amortization of goodwill
Increase (decrease) in allowance for doubtful accounts
Increase (decrease) in other provision
Increase (decrease) in retirement benefit liabilities
Interest income
Interest expenses
Loss (gain) on sale and retirement of fixed assets
Loss on business liquidation
Decrease (increase) in trade receivable-trade
Decrease (increase) in inventories
Increase (decrease) in notes and accounts payable-trade
Increase (decrease) in other current liabilities
Other
SubtotalInterest and dividend income received
Income expenses paid
Income taxes paid
Net cash provided by (used in) operating activities
Net cash provided by (used in) investing activities
Payments into time deposits
Proceeds from withdrawal of time deposits
Purchase of marketable securities
Proceeds from sale and redemption of marketablesecurities
Purchase of property, plant and equipment andintangible assets
Proceeds from sales of property, plant and equipment
and intangible assets
Purchase of other depreciable assets
Other
Net cash provided by (used in) investing activities
Net cash provided by (used in) financing activities
Dividends paid
Repayments of lease obligations
Net cash provided by (used in) financing activities
Effect of exchange rate change on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period- 7 -Six months ended
Sep. 30, 2020

2,950
1,352
65
250
0
(39)
27
(59)
－
9
－
2,903
(546)
(500)
(1,239)
88
5,261
63
－
(615)
4,709

3,281
1,631
42
246
1
52
(7)
(60)
12
24
464
572
(1,481)
374
1,178
(14)
6,318
70
(12)
(822)
5,553

(2,049)2,100(2,000)(1,657)
3,122
－

2,000

2,000

(2,387)(5,750)

100

14

(47)
0
(2,283)(141)(4)(2,417)

(841)
(43)
(884)
(329)
1,212
9,464
10,676(961)(68)(1,030)(209)
1,897
14,462
16,360

The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)(4) Notes to Consolidated Quarterly Financial Statements(Notes on Premise of Going Concern)
No items to report.
(Notes in case of Changes in Marked Amount of Shareholders’ Equity)
No items to report(Additional Information)(Accounting Estimates for the COVID-19 Pandemic)
At the end of the previous fiscal year, it was assumed that the impact of the COVID-19 on our group would continue during
the first half of FY2021, albeit gradually recovering. However, based on information available at the time of preparation of theconsolidated financial statements for the second quarter of the fiscal year under review, the Company revised the assumptionthat the impact will continue for a certain period of FY2022, although it varies by region. The Company made estimates andjudgments regarding the impairment loss of goodwill and the recoverability of deferred tax assets at the end of the second quarterof the fiscal year under review based on revised assumptions, but no indicators of impairment have been identified for goodwill,
and the Company has determined that no additional valuation allowance is required for the recoverability of deferred tax funds.
Due to the high degree of uncertainty associated with the impact of the COVID-19, any change in the above assumptions
could have an impact on the Group's financial condition and results of operations.
(Segment Information)【Segment Information】
I Equivalent period of previous fiscal year (From Apr. 1, 2019 to Sep. 30, 2019)
It is described in II the six months ended September 30, 2020 (Matters related to changes and others by reportable segment).
II Six months ended September 30, 2020 (From Apr. 1, 2020 to Sep. 30, 2020)
This information is omitted because the Company consists of a single segment.
(Matters related to changes and others by reportable segment)
The Company has established business divisions for each product and service, and each business division has formulated acomprehensive strategy for the products and services it handles, including its subsidiaries, and developed its businessactivities. In April 2020, however, we decided to dissolve a business division structures with the aim of becoming a drug
discovery company that creates new modalities by integrating the management resources that each business division had
and advancing the development of bio-drug discovery platform technologies.
As a result of this organizational review, the Bioindustry and Gene Therapy business segments, which were previously
reported segments, have been changed to a single business segment from the first quarter of the fiscal year under review,
and as a result, the reportable segments have become a single segment.
Due to this change, segment information for the second quarter of the previous fiscal year and the second quarter of thecurrent fiscal year has been omitted.

- 8 -The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)
3. Supplementary Information(1) Trends in Key Management Indicators1). Cash Flow
Six months ended
Sep. 30, 2019
Term
(Apr. 1, 2019 – Sep. 30, 2019)
Net cash provided by (used(Millions of yen)Six months ended
Year ended
Sep. 30, 2020
Mar. 31, 2020
(Apr. 1, 2020 - Sep. 30, 2020) (Apr. 1, 2019 - Mar. 31, 2020)

4,709

5,553

6,339

Net cash provided by (usedin) investing activities(2,283)(2,417)(212)

Net cash provided by (usedin) financing activities(884)(1,030)(946)in) operating activities

2). Net Sales by Region(Millions of yen)
Year ended
Six months ended Sep. 30, 2019 Six months ended Sep. 30, 2020
Mar. 31, 2020
(Apr. 1, 2019 – Sep. 30, 2019) (Apr. 1, 2020 - Sep. 30, 2020)(Apr. 1, 2019 - Mar. 31, 2020)

Japan

6,816

6,906

14,804

U.S.

3,954

3,634

8,011

China

3,023

3,449

6,391

918

1,394

1,877

1,596

1,678

3,207

Asia excluding Japan and
China
Europe
Other
Total

141

330

271

16,45017,39334,5653). R&D expenses by reportable segment
Disclosure is omitted because the reportable segments have been changed to a single segment from the first quarter ofthe current fiscal year.

- 9 -The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)(2) Comparative Consolidated Statement of Profit
Six months ended
Sep. 30, 2019
Actual(Rounded down to one million yen)Six months ended
Year on year Year on year
Sep. 30, 2020
ChangeRatio
Actual（Net Sales）
Research reagents
Scientific instruments
Contract services
Gene therapy

11,824
620
1,961
2,044

13,336
466
3,373
215

1,512
(153)
1,411
(1,828)112.8%
75.3%
172.0%
10.6%

Total net sales

16,45017,393942

105.7%

16,45017,393942

105.7%

Cost of sales

6,121

5,565

(555)

90.9%

Gross profits

10,32911,827

1,498

114.5%

SG&A expenses

7,293

8,090

797

110.9%

Transportation expenses
Advertising expenses
Promotion expenses
R&D expenses
Administrative expenses, other
Enterprise taxes (external standards taxation)

186
33
299
1,858
4,766
149

336
31
276
2,403
4,883
160

149
(2)
(23)
544
116
11

180.5%
92.4%
92.3%
129.3%
102.4%
108.0%

Operating profit

3,035

3,736

701

123.1%

130

143

12

109.8%

203

59

(144)

29.3%

2,961

3,820

858

129.0%(Operating profit and Loss)
Net sales(Non-operating profit and Expenses)
Non-operating profit
Non-operating expenses
Ordinary profit(Extraordinary profit & Losses)
Extraordinary profit
Extraordinary losses
Profit before income taxes and others
Income taxes
Net Income
Net income (loss) attributable to non-controllinginterests
Net income attributable to owners of the parent
Depreciation and amortization(Property, plant and equipment and intangible assets)
Amortization of goodwill

0

1

0

251.6%

12

539

527

4440.5%

2,950

3,281

331

111.2%

870

990

120

113.8%

2,080

2,291

211

110.2%

4

16

12

358.5%

2,075

2,274

199

109.6%

1,352

1,631

279

120.7%

250

246

(4)

98.4%

※1 Sales of “Other” in the previous fiscal year were included in “Research reagents” from the first quarter of current fiscal year, andresults for the second quarter of the previous fiscal year in this table have been reclassified to reflect this change.
※2 The disclosure of profit and loss by segment (operating profit) is omitted because the reporting segments were changed to a single
segment from the first quarter of the current fiscal year.

- 10 -

The original disclosure in Japanese was released on November 10, 2020 at 15:00 (GMT+8)(3) Comparative Statement of Profit Relating to Consolidated Earnings Forecasts（Net Sales）

Year ended
Mar. 31, 2020

Year ending
Mar. 31, 2021

Year ending
Mar. 31, 2021

ActualPrevious forecast

Current forecast(Rounded down to one million yen)Previous Previous
forecast
forecast
ChangeRatio

Year on year
ChangeYear on year
Ratio

（Net Sales）

Research reagents

24,84027,60329,9405,100

120.5%

2,337

108.5%

Scientific instruments

1,242

1,227

1,454

211

117.0%

226

118.5%

Contract services

6,186

9,850

8,539

2,352

138.0%(1,310)86.7%

Gene therapy

2,295

918

865

(1,430)

37.7%

(53)

94.2%

Total Net Sales

34,56539,60040,8006,234

118.0%

1,200

103.0%Net Sales

34,56539,60040,8006,234

118.0%

1,200

103.0%

Cost of sales

13,45916,223

15,4201,961

114.6%

(802)

95.1%

Gross profits

21,10523,37625,3794,273

120.2%

2,002

108.6%

SG&A expenses

14,83016,876

17,3792,548

117.2%

502

103.0%

Transportation expenses

492

665

693

200

140.7%

27

104.2%

Advertising expenses

73

70

58

(14)

80.5%

(11)

84.0%

(Operating profit and Loss)

Promotion expenses

579

550

724

145

125.0%

174

131.7%

R&D expenses

3,869

5,121

5,173

1,303

133.7%

51

101.0%

Administrative expenses, other
Enterprise taxes(external standards taxation)

9,511

10,157

10,399888

109.3%

242

102.4%

305

311

329

24

108.0%

17105.8%

Operating profit

6,274

6,500

8,000

1,725

127.5%

1,500

123.1%

316

293

307

(8)

97.2%

14

105.0%(Non-operating profit and Expenses)
Non-operating profit
Non-operating expenses

243

193

207

(35)

85.3%

14

107.6%

6,347

6,600

8,100

1,752

127.6%

1,500

122.7%

Extraordinary profit

0

－

1

0

255.5%

1－

Extraordinary losses

Ordinary profit(Extraordinary profit & Losses)

914

627

679

(235)

74.3%

51

108.2%

Profit before income taxes andothers

5,433

5,972

7,421

1,988

136.6%

1,449

124.3%

Income taxes

1,601

1,961

2,394

792

149.5%

433

122.1%Net Income

3,831

4,010

5,027

1,195

131.2%

1,016

125.3%Net income (loss) attributable tonon-controlling interests
Net income attributable toowners of the parent

11

10

27

15

227.3%

16

248.7%

3,819

4,000

5,000

1,180

130.9%

1,000

125.0%

Depreciation and amortization(Property, Plant and equipment
and intangible assets)

2,921

3,268

3,305

383

113.1%

36

101.1%

496

486

486

(9)

98.0%

0

100.1%

Amortization of goodwill※1 Sales of “Other” in the previous fiscal year were included in “Research reagents” from the current consolidated fiscal year, andresults for equivalent period of previous fiscal year in this table have been reclassified to reflect these changes.
※2 The disclosure of profit and loss by segment (operating profit) is omitted because the reporting segments were changed to a single
segment from the current consolidated fiscal year.

- 11 -